The main symptoms of acute myeloid leukaemia (AML) happen because your bone marrow can’t make enough healthy white blood cells, red blood cells and platelets. Symptoms of AML include:
- feeling tired and weak
- being breathless, especially during exercise
- frequent infections
- unexplained bleeding, such as nosebleeds, bleeding gums and heavy periods in women
- bruising easily
- a rash of dark red/purple spots (called petechiae)
Other symptoms are caused by leukaemia cells collecting in various parts of your body. These include:
- a full feeling or pain in your upper abdomen (tummy) caused by your liver and spleen being enlarged
- swelling of your gums
- lumps under your skin caused by leukaemia cells
Your symptoms may come on quickly – over a matter of days or weeks – or they may take months to develop.
Most people with these symptoms don’t have AML but if you have them, see your GP.
Your GP will ask about your symptoms and examine you. If your symptoms suggest that a blood test may be helpful, your GP will arrange this. If your blood test shows that you have acute myeloid leukaemia (AML) you’ll normally be admitted to hospital within 24 hours. You’ll then be under the care of a haematologist (a doctor who specialises in conditions of the blood).
Your doctor will offer you tests to confirm the diagnosis and investigate which type of leukaemia you have. These tests will include:
- more blood tests – to check your blood cells and also see how well your kidneys and liver are working
- a bone marrow biopsy. Your doctor will use a needle to remove a small sample of your bone marrow to be examined under a microscope
- a chest X-ray to check your lungs
If you’re diagnosed with AML, your doctor may offer you further tests on your bone marrow sample to find out what type it is. This can help them decide the most appropriate treatment. Further tests include:
- specific tests on the leukaemia cells to confirm exactly what type they are
- tests to look at the genetic make-up of the leukaemia cells
You may hear your doctor referring to your treatment for acute myeloid leukaemia (AML) in two phases.
- Remission induction to get rid of the cancer.
- Consolidation treatment to prevent the cancer coming back (a relapse).
Treatment for AML can last many months and is likely to cause some side-effects. These include hair loss, increased tiredness and feeling sick. Your doctor will discuss the probable risks and benefits of treatment in your individual circumstances.
Remission is when no leukaemia cells (or only a very few) can be detected in your bone marrow. You will also have normal levels of healthy blood cells in your blood. The main treatment for causing remission in AML is chemotherapy. This uses medicines to destroy cancer cells in your bone marrow. At first, you’ll probably need to stay in hospital for about a month. This is because the treatment is quite demanding and you’ll need support from hospital staff.
You’re likely to be given a mixture of chemotherapy medicines. It’s thought that using a combination works better than just one medicine on its own. You will usually have these different medicines in cycles, with rest periods in between. Most patients will need a total of four cycles of chemotherapy which usually takes about six months to complete.
If you have a type of AML known as acute promyelocytic leukaemia (APML), you’ll also be given a medicine called all trans-retinoic acid (ATRA). ATRA (or tretinoin) works by making your abnormal white blood cells develop into normal cells and is given as a tablet. It’s important that you receive this medicine as soon after being diagnosed as possible because it can prevent complications from developing.
Once your AML has gone into remission you’ll need to have further treatment to prevent it from returning. This is called consolidation treatment and may involve the following.
- Further courses of intensive chemotherapy. Patients with AML will usually have between one and three cycles of consolidation treatment.
- A bone marrow (stem cell) transplant. This is when somebody else donates healthy bone marrow or stem cells, which are transferred into your body.
Many possible new treatments for AML are being tested in clinical trials all the time. These include new chemotherapy medicines, and different types of stem cell transplant and biological therapies that change chemical pathways inside cells. You may be able to take part in a clinical trial to test one of these new treatments. See our frequently asked questions, below, for information about taking part in a clinical trial. And have a chat with your doctor about it.
Doctors don’t yet completely understand why people get acute myeloid leukaemia (AML), although lots of research is being done to try to find out. However, they do know that there are several things that increase the risk of getting AML.
- Exposure to radiation.
- Smoking. This is thought to double your risk of getting AML.
- Exposure to certain cancer-causing substances (carcinogens) such as benzene.
- Previous cancer treatment. If you’ve had chemotherapy in the past, you’re slightly more likely to develop acute leukaemia. It’s important to remember that this small risk of leukaemia is outweighed by the benefits you got from having your cancer treated.
- Having certain other blood disorders, including myelodysplasia and chronic myeloid leukaemia.
- Genetic disorders such as Down's syndrome.
How will my treatment affect my daily life? How will my treatment for acute myeloid leukaemia (AML) affect my daily like?
Having treatment for AML will probably bring a lot of changes to your daily life for a while. These changes may depend, to some extent, on your usual activities and how you react to the type of treatment you have.
Getting a diagnosis of AML can bring great changes to your life because you may get ill quite quickly and need immediate treatment in hospital. While you’re having repeated courses of chemotherapy, you’ll need to spend a lot of time in hospital with only short breaks in between. These are usually less than a week. During these breaks you’re likely to feel very tired, which can affect how you cope with your daily activities. This tiredness may continue even after resting and can carry on for some time after your treatment has finished.
Ask for support and help from your family and friends to help you manage with your daily routine. Try to do some gentle exercise, eat a healthy, balanced diet with plenty of fruit and vegetables, and get plenty of rest. These will all help you cope with tiredness.
There are likely to be practical issues such as financial, work and legal matters to organise. Your doctor will be able to put you in touch with people who can help you manage these things.
You may have very mixed emotions or negative feelings that can continue once you’ve finished treatment. Everyone deals with their diagnosis differently and it’s important that you feel able to talk about things with someone if you want to. This might be a family member or friend, or someone involved in your treatment.
There are lots of organisations and support groups that offer help and advice if you want to contact them. It may help you and your family to talk to other people who’ve been through a similar experience. See our resources section for some useful contact details.
I'm in remission - is it likely to come back? My acute myeloid leukaemia (AML) is in remission – is it likely to come back?
It’s possible that your AML will come back, even if you’re in remission for several years. This can depend on a number of things, including your age and what type of AML you have.
Treatment for AML aims to get rid of the cancer and also to prevent it from coming back (relapsing). How successful this is varies according to your age, the type of AML that you have and how well the chemotherapy works. About half of all people under the age of 50 who are diagnosed with AML will live for at least five years. Some of these people will be cured, but for others the AML will come back. In people who are over 50 when they are diagnosed with AML, about one out of eight will live for five years or more.
If your AML does come back, it’s possible to have further treatment. This will involve more chemotherapy first and if this works, you may be offered a bone marrow (stem cell) transplant. If it isn’t possible to get your AML into remission again, your doctor may recommend treatments to relieve your symptoms.
Your doctor will discuss with you the best options for your personal circumstances.
Treatment for AML is often given as part of a clinical trial. Talk to your doctor to find out whether this is an option for you.
Clinical trials are used to test how well a treatment works and how safe it is before it can be made widely available to people. AML can be difficult to treat and doctors are always trying to improve the treatments they use for it. Because of this many patients getting treatment for AML take part in a clinical trial. This may be to test a new medicine or treatment, or to test a new combination of existing treatments. In the UK, most hospitals enter patients into the National Cancer Research Institute AML trials. This is one of the largest multicentre trials worldwide and recruits several thousand patients.
If your doctor suggests taking part in a clinical trial they will discuss the details with you. It’s important that you understand exactly what it involves and it’s your decision whether you take part or not. The following are some questions that you may wish to ask.
- What is the aim of the trial?
- How will the trial be of benefit to me and other people?
- What are the potential side-effects, risks or benefits?
- What happens if my condition gets worse?
- Can I decide to stop doing the trial once I’ve started it?
- What will happen after the trial is finished?
Remember, new treatments aren’t always better. Sometimes treatments don't work as well or side-effects are worse than existing treatments. Your doctor should give you enough information to help you decide whether you wish to take part in a clinical trial.
- Kumar, P, Clark, M. Clinical medicine. 8th ed. Edinburgh: Saunders; 2012
- Acute myelogenous leukaemia. BMJ Best Practice. www.bestpractice.bmj.com, published 4 February 2015
- Acute myelogenous leukemia. Medscape. www.emedicine.medscape.com, published 15 August 2014
- Acute myeloid leukaemia. PatientPlus. patient.co.uk/patientplus.asp, published 6 September 2013
- Referral guidelines for suspected cancer. National Institute for Health and Care Excellence (NICE), 2005. www.nice.org.uk
- Haematological malignancies. Oxford handbook of oncology (online). Oxford Medicine Online. www.oxfordmedicine.com, published June 2011 (online version)
- Map of Medicine. Acute leukaemia. International View. London: Map of Medicine; 2013 (Issue 4)
- Cancer statistics for the UK. Cancer Research UK. www.cancerresearchuk.org, published 16 June 2014
- Acute myeloid leukaemia. Cancer Research UK. www.cancerresearchuk.org, published 12 February 2014
- Tretinoin (Vesanoid, ATRA). Cancer Research UK. www.cancerresearchuk.org, published 24 January 2014
- Coping with cancer. Cancer Research UK. www.cancerresearchuk.org, published 6 March 2014
- Adult acute myeloid leukemia treatment (PDQ). National Cancer Institute. www.cancer.gov, published 9 January 2015
- About clinical trials. Medical Research Council, Clinical Trials Unit. www.ctu.mrc.ac.uk, accessed 3 March 2015
We’d love to know what you think about what you’ve just been reading and looking at – we’ll use it to improve our information. If you’d like to give us some feedback, our short form below will take just a few minutes to complete. And if there's a question you want to ask that hasn't been answered here, please submit it to us. Although we can't respond to specific questions directly, we’ll aim to include the answer to it when we next review this topic.
Let us know what you think using our short feedback form Ask us a question
Reviewed by Dylan Merkett, Bupa Health Content Team, July 2015.
About our health information
At Bupa we produce a wealth of free health information for you and your family. We believe that trustworthy information is essential in helping you make better decisions about your health and care. Here are just a few of the ways in which our core editorial principles have been recognised.
Information StandardWe are certified by the Information Standard. This quality mark identifies reliable, trustworthy producers and sources of health information.
What our readers say about us
But don't just take our word for it; here's some feedback from our readers.
“Simple and easy to use website - not alarming, just helpful.”
“It’s informative but not too detailed. I like that it’s factual and realistic about the conditions and the procedures involved. It’s also easy to navigate to areas that you specifically want without having to read all the information.”
“Good information, easy to find, trustworthy.”
Meet the team
Head of Health Content
- Dylan Merkett – Lead Editor
- Natalie Heaton – Specialist Editor, User Experience
- Pippa Coulter – Specialist Editor, Content Library
- Alice Rossiter – Specialist Editor, Insights
- Laura Blanks – Specialist Editor, Quality
- Michelle Harrison – Editorial Assistant
Our core principles
All our health content is produced in line with our core editorial principles – readable, reliable, relevant – which are represented by our diagram.
In a nutshell, our information is jargon-free, concise and accessible. We know our audience and we meet their health information needs, helping them to take the next step in their health and wellbeing journey.
We use the best quality and most up-to-date evidence to produce our information. Our process is transparent and validated by experts – both our users and medical specialists.
We know that our users want the right information at the right time, in the way that suits them. So we review our content at least every three years to keep it fresh. And we’re embracing new technology and social media so they can get it whenever and wherever they choose.
Here are just a few of the ways in which the quality of our information has been recognised.
The Information Standard certification scheme
You will see the Information Standard quality mark on our content. This is a certification programme, supported by NHS England, that was developed to ensure that public-facing health and care information is created to a set of best practice principles.
It uses only recognised evidence sources and presents the information in a clear and balanced way. The Information Standard quality mark is a quick and easy way for you to identify reliable and trustworthy producers and sources of information.
Certified by the Information Standard as a quality provider of health and social care information. Bupa shall hold responsibility for the accuracy of the information they publish and neither the Scheme Operator nor the Scheme Owner shall have any responsibility whatsoever for costs, losses or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of Bupa.
British Medical Association (BMA) patient information awards
We have received a number of BMA awards for different assets over the years. Most recently, in 2013, we received a 'commended' award for our online shared decision making hub.
If you have any feedback on our health information, we would love to hear from you. Please contact us via email: firstname.lastname@example.org. Or you can write to us:
Health Content Team
15-19 Bloomsbury Way